Citadel Advisors
MREO

Citadel Advisors’s Mereo BioPharma MREO Stock Holding History

Citadel Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,171,632
Closed -$6.04M – 13568
2025
Q3 		$6.53M Buy
3,171,632
+2,410,973
+317% +$4.44M ﹤0.01% 3893
2025
Q2 		$2.06M Buy
760,659
+417,006
+121% +$1.01M ﹤0.01% 5650
2025
Q1 		$773K Buy
343,653
+29,703
+9% +$84K ﹤0.01% 7530
2024
Q4 		$1.1M Buy
313,950
+183,692
+141% +$722K ﹤0.01% 6812
2024
Q3 		$535K Sell
130,258
-278,731
-68% -$1.15M ﹤0.01% 8117
2024
Q2 		$1.47M Buy
408,989
+365,082
+831% +$1.18M ﹤0.01% 5868
2024
Q1 		$145K Sell
43,907
-280,912
-86% -$951K ﹤0.01% 10817
2023
Q4 		$750K Sell
324,819
-1,917,606
-86% -$3.67M ﹤0.01% 7248
2023
Q3 		$2.89M Buy
2,242,425
+473,982
+27% +$629K ﹤0.01% 4544
2023
Q2 		$2.33M Sell
1,768,443
-1,279,517
-42% -$1.48M ﹤0.01% 4891
2023
Q1 		$2.15M Sell
3,047,960
-14,372
-0.5% -$12.9K ﹤0.01% 5217
2022
Q4 		$2.3M Sell
3,062,332
-13,555
-0.4% -$11.1K ﹤0.01% 5219
2022
Q3 		$2.65M Buy
3,075,887
+312,462
+11% +$382K ﹤0.01% 5059
2022
Q2 		$3.1M Sell
2,763,425
-1,142,910
-29% -$886K ﹤0.01% 4706
2022
Q1 		$4.38M Sell
3,906,335
-94,479
-2% -$122K ﹤0.01% 4439
2021
Q4 		$6.4M Sell
4,000,814
-73,806
-2% -$148K ﹤0.01% 3863
2021
Q3 		$9.86M Buy
4,074,620
+1,120,552
+38% +$2.97M ﹤0.01% 3108
2021
Q2 		$9.36M Buy
2,954,068
+516,810
+21% +$1.73M ﹤0.01% 3184
2021
Q1 		$8.21M Sell
2,437,258
-1,678,197
-41% -$5.93M ﹤0.01% 3283
2020
Q4 		$14.7M Buy
4,115,455
+4,097,346
+22,626% +$10.3M ﹤0.01% 2151
2020
Q3 		$47K Buy
+18,109
New +$52.9K ﹤0.01% 9623

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors's MREO Position: Q4 2025 in Review

Citadel Advisors sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 3,171,632 shares — an estimated $6.04M sold.

Citadel Advisors first reported a position in MREO in Q3 2020 and held it in 21 quarters. The position peaked at $14.7M in Q4 2020. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Citadel Advisors reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 3,171,632 Mereo BioPharma shares in Q4 2025, an estimated $6.04M.
  • Citadel Advisors first reported a position in Mereo BioPharma in Q3 2020 and held it in 21 quarters.
  • Citadel Advisors's Mereo BioPharma position peaked at $14.7M in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.